Lupin Ltd specializes in Pharmaceuticals within the Healthcare sector.
Lupin Ltd, with Security Code 500257, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
Date Begin | Date End | Net Sales | Net Profit | Total Income | Diluted EPS for continuing operation | Other Expenses | Other Income | Depreciation and amortisation expense | Profit (+)/ Loss (-) from Ordinary Activities before Tax |
---|---|---|---|---|---|---|---|---|---|
2024-01-01 | 2024-03-31 | 33,958.80 | 3,840.80 | 34,272.20 | 8.40 | -9,666.50 | 313.40 | -2,900.40 | 4,281.60 |
2024-01-01 | 2024-03-31 | 33,958.80 | 3,840.80 | 34,272.20 | 8.40 | -9,666.50 | 313.40 | -2,900.40 | 4,281.60 |
2023-10-01 | 2023-12-31 | 41,157.50 | 9,164.40 | 41,389.10 | 20.05 | -10,374.40 | 231.60 | -1,451.80 | 10,839.60 |
2023-10-01 | 2023-12-31 | 51,974.10 | 6,187.00 | 52,267.80 | 13.41 | -15,601.30 | 293.70 | -2,572.00 | 7,361.00 |
Compounded Sales Growth | |
---|---|
10 Years: | 5% |
5 Years: | 5% |
3 Years: | 10% |
TTM: | 30% |
Compounded Profit Growth | |
---|---|
10 Years: | 0% |
5 Years: | 6% |
3 Years: | 24% |
TTM: | 466% |
Stock Price CAGR | |
---|---|
10 Years: | 4% |
5 Years: | 17% |
3 Years: | 12% |
1 Year: | 79% |
Compounded Sales Growth | |
---|---|
10 Years: | 6% |
5 Years: | 6% |
3 Years: | 10% |
TTM: | 20% |
Compounded Profit Growth | |
---|---|
10 Years: | 0% |
5 Years: | 21% |
3 Years: | 18% |
TTM: | 367% |
Stock Price CAGR | |
---|---|
10 Years: | 4% |
5 Years: | 17% |
3 Years: | 12% |
1 Year: | 79% |
Solosec is indicated for the treatment of bacterial vaginosis in adult and pediatric females 12 years of age and older.
The generic version of Crestor is available in 5 mg, 10 mg, 20 mg, and 40 mg strengths.
Gaviscon Liquid Antacid is indicated for the relief of heartburn, acid indigestion, and sour stomach.
The collaboration will focus on the development and commercialization of biosimilars in the areas of oncology, immunology, and other therapeutic areas.